With an emphasis on effective and economic patient care, Ayrtons has a portfolio of trusted treatments.

  • Glytrin Ret

    Glytrin Spray

    Developed in house a 400µg per metered dose oro-mucosal (sublingual) spray solution of Glyceryl Trinitrate (GTN) for the treatment of acute angina pectoris and prevention of inducible angina. Ayrtons undertook the roll out of the regulatory approval to multiple juristictions then sold the asset to EU speciality Pharma company.

  • Ayr005

    AYR 005

    An inhouse development of generic US Metered dose inhaler, licenced to a top 10 global generics firm.

  • Betadine Ret

    Betadine Dry Powder Spray

    Pressurised aerosol spray containing Povidone Iodine 2.5% w/w for the treatment and prevention of infection in wounds, including ulcers, burns, cuts and other minor injuries. Purchased UK rights from EU speciality pharma company, improved commercial proposition and sold to globally operating speciality Pharma company.

  • Voke


    Combing IP purchased from Kind consumer & Senzer limited Ayrtons Saunders has completely redeveloped the original product delivering improved consumer experience including a 50% reduction on the retail price by means of a new reusable device and separately available refill canisters. Ayrtons Saunders is offering for sale or licence, the intellectual property portfolio, approved MA’s and supply chain capable of supplying up to 18m units per annum.


Ayrtons is investing in new products and is interested in collaborating in the co-development, in/out-licensing and distribution internationally of aerosol products (in particular for respiratory, wound/skin, cardiac and systemic treatments) and other high value products for speciality, novel and niche markets.